Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

cash4

07/31/15 1:11 AM

Post #2

Market Announcement – Listing of Wholly Owned Subsidiary
The Directors of iQnovate Limited (NSX:IQN) (the Company) are pleased to announce that the
Board has resolved to float its wholly owned pharmaceutical contract sales subsidiary,
FarmaForce Pty Ltd (FarmaForce), via a new proposed ASX listing. The Company has
committed to an IPO of FarmaForce and listing on the ASX by the end of the 3rd quarter 2015.
Preliminary market research has indicated significant demand for this raising and it is
anticipated that the proposed offer will be oversubscribed.
The key details of this proposed new float, which is subject to all necessary approvals being
obtained, are:
• Offer to be made via a Prospectus
• Capital Raising – it is proposed to raise at least $4 million
• iQnovate Ltd shareholders will not be offered a priority entitlement under the offer as
the company intends to retain a majority shareholding in FarmaForce
• iQnovate Ltd – the Company’s shareholding in FarmaForce will be diluted by the
proportion of the offer.
The funds raised will be applied to working capital and the continued development of the
FarmaForce Pty Ltd business.
iQnovate Limited Chief Executive Officer Dr George Syrmalis said “Farmaforce is Australia’s
most innovative pharmaceutical sales organization currently engaging in deals with
multinational pharmaceutical companies. The company’s growth since inception has been
remarkable and a listing on the ASX will provide a platform for further corporate growth”.

https://www.nsxa.com.au/ftp/news/021729866.PDF

cash4

07/29/15 5:44 PM

Post #1

ASX ANNOUNCEMENT
Appointment as Lead Manager – iQnovate Ltd Private Placement
iQ3Corp Ltd (ASX:iQ3) is pleased to announce that it has been appointed as
lead manager and to capital raise for the current private placement of
iQnovate Ltd (iQN) shares. The placement of IQN shares to sophisticated and
professional investors is expected to raise up to $5,000,000.
For more information please contact the iQ3Corp Investor Relations Team.

http://iqnovate.com/wp-content/uploads/2015/06/ASX_iQN_Private_Placement_Announcement20150529-.pdf

IQnovate Ltd (IQNDY)

Followers	0	Posters	1
Posts (Today)	0	Posts (Total)	2
Created	07/29/15	Type	Free
Moderators

Welcome to IQnovate

http://iqnovate.com/

iQnovate is a publicly listed life sciences organisation trading on the National Stock Exchange of Australia (IQN) and cross listed on the GXG Main Quote in Europe (IQN) and the OTCQB in New York (IQNDY).

The life sciences sector is one of the best performing industries globally. Through the intersection of dedicated medical and clinical research, the life sciences sector supports the development of human therapeutics, clinical diagnostics and medical devices that empower people to lead happier and healthier lives. It is made up of a diverse range of industry participants including biotechnology firms, pharmaceutical conglomerates, manufacturing companies, research organisations, state and federal government departments, academic institutions, industry bodies, healthcare organisations and medical and allied health groups within the clinical setting as well as specialist providers who deliver support functions, products and services that are essential to the functioning of the sector.

The forecast for the increasing demand in the life sciences sector is being driven by considerable macro-forces including:
A rapidly increasing global population
An aging populace
More sedentary lifestyles leading to obesity and other related health concerns including heart disease, diabetes and cancer
An increase in the incidence of both infectious and chronic diseases
Technological and medical advances
Increased wealth in the emerging world and;
Improved access to affordable healthcare in many parts of the world

Along with two wholly owned subsidiaries, FarmaForce Pty Ltd and Clnical Research Corporation Pty Ltd, iQnovate is uniquely positioned to provide integrated scientific advisory, IP asset management and contract drug development services to the global life sciences sector.

http://farmaforce.com.au

FarmaForce is a contract sales organisation
catering to the Australian Pharmaceutical
Industry.

http://crcaustralia.com

Clincal Research Corporation (CRC)is a life science organisation providing
strategic Medical Affairs, targeted Clinical
Affairs and specialist Scientific Advisory
and Due Diligence services to the
Australian biopharmaceutical sector.
https://www.linkedin.com/company/clinical-research-corporation

The leadership team across the three organisations brings decades of drug development experience as well as proven expertise in navigating the complex hurdles faced by stakeholders on life science projects.

This presents a compelling opportunity for investors to become active in the life sciences space.

To register your interest in investing in the iQnovate philosophy, please contact us today:
Phone: +61 2 8239 5400
Level 3 & 6, 222 Clarence Street
Sydney NSW Australia 2000
email: info@crcaustralia.com

Social Media
https://www.facebook.com/TheiQGroup